Appreciate the help... was on mobile earlier. Seems otc has it listed the same.

Appreciate the help... was on mobile earlier. Seems otc has it listed the same.

Last time I checked a couple months ago it was 68 Million O/S.

Any idea the current SS here?

Looks like this is dead in the water for the next few months, will perhaps buy a few whe it goes sub penny, cane sure is the master of disaster...... Two years of release "soon" has taken its toll, will probably bk cbis as well

Very bad volume so far 2 days in a row.. Suspected dilution tomorrow or next week.. I'll be ready to jump in :)

Bet ENDO closes over .03 today.eom

Chillax

Why dont you pull your head out of you arse ....sounds like your brain needs some oxygen.

ENDO

I called and they said the price will go sky high soon and they are preparing for this. So your guess was wrong. Thanks for playing though.

Yeah. Everyone should know by now, it's on ur brokage page .. All pinks and OTC halted

FINRA has halted OTC info temporally on all quotes.Probably due to twitter overloadThe previous post is irresponsible.

The sec revoked it ,, all ur shares are gone

Is this company done already?

Anything going on today? It seems to be halted.

Greens-Insiders are telling me that Saladin lost $200.00 trading XCHC. Lol

With the Colorado Tax now legal ENDO can sell their products without fear and get Taxed and report income on Earnings report.

ENDO has no debt so when earnings come in and with the low float we could see 1.00 next year

http://www.huffingtonpost.com/2013/11/05/marijuana-taxes_n_4219133.html

NEWS....

No

ENDO ? hello anyone there $$$$$$
greens12

Elite Pharma:
--Specializes in the development of oral ABUSE RESISTANT OPIODS
Recent news out of FDA keeps eliminating all of Elites competition in this sector.


--Billion dollar plus pipeline
--8 FDA approved drugs: hydromorphone, phentermine 37.5 mg, lodrane D, methadone, phendimetazine, phentermine 15mg, phentermine 30mg, naltrexone 50mg
--4 quarters of increasing revenues
--launched drugs continue to gain market share
--cash flow positive (CFP) this quarter or next, not including R&D cost
--600 % increase in market cap in 2 years
--ELI-216 is a controlled release 24 hr abuse resistant(ART) oxycodone requiring Phase III clinical trials, which could start any time
--a partner for commercialization of ELI-216 could be announced any day
--ELI-216 is a priority with Elite and further along than most people think, per the CEO
--1st patent for ELI-216 8/182,836 abuse resistant oral formulations and method of use thereof (approved May 22, 2012) method for making an abuse resistant drug
--2nd patent for ELI-216 8/425.933 formerly 12/640,344(approval due week of April, 21 2013) combined with first patent, gives Elite a hammerlock on superior 2 bead ART: formulation to make an existing drug abuse resistant
--patent 13/863,764 Child Continuity Data strengthens Elite's "Hammer Lock" on 2-bead ART giving it triple patent propietary protection for 20+ years
--eventually superior 2-bead abuse resistant opiods(which can not be easily defeated) will replace the inferior abuse deterrent(easily defeated) opiods now on the market
--Elites ART is modular, not for just oxycodone it can be used on ALL opiods
--NE 30 polymer for sequestering naltrexone was found to be far superior to other polymers
--BE and PK studies for ART progressing, some were due finished by March 31, 2013
--Patent pending 13/379,481 microtablets for use with abuse resistant products
--Patent pending 13/379,486 microtablets 0.25-1.0mm, smallest in the industry for use with ALL medicines
--patent 12/075,816 for Sequestering polymer acrylic co-polymer composition: ON HOLD while Elite and lawyers Washburn & Woodcock strategize to add more claims

--the STOPP ACT - a bill before Congress NOW, introduced by US Rep's Rahall, Rogers and Keating. The law will prohibit any old-formula opiod from entering the market if the FDA has an equivalent abuse deterrent/resistant opiod approved
--FDA's Purdue ruling April 16, 2013 : prohibits new original non-abuse resistant oxycodone from being made in generic form, unless it has an abuse deterrent/resistant properties. FDA will not accept or approve any ANDA applications based on the original OxyContin formulation
--the FDA decision basically requires generic companies to buy or develop their own abuse deterrent/resistant technology: it effectively eliminates much of Elite's competition which has no ART thus making Elite's 2-bead ART MORE VALUABLE
--going foward all new generic and probably NDA branded opiods will be required to have Abuse deterrent/resistant properties

--Elite owns 10% of Novel Labs, Gavis and recently Wintac: Novel has approached Elite for monetization
--Novel Labs net worth growing rapidly, 31 FDA approved drugs, including a new generic morning after(Plan B) pill
--estimates for 10% value of Novel range from 10 to 50 million dollars
--sale of Novel Labs will make Elite's financials rock solid by paying off ALL debt, paying for ELI-216 Phase III clinical trials, and allowing for the purchase of more ANDA's
--CEO Bought 500,000 shares July 2010, officers being paid with stock
--CEO Jerry Trepple loaned the co. 1 million dollars unsecured (non-dilutive)
--CTO of Elite is Epics president and works for shares of ELTP
--VP @ Actavis/Mikah is a special consultant to EPIC
--multiple partners have no concerns: Watson/Actavis, Mikah, Epic, TAGI, The Pharm Network, ECR, Precision Dose, Celgene Corp and the undisclosed Hong Kong Pharma
--interest paid in full on loans
--New Jersey(NJEDA) tax credits
--contracting deals with other pharmas
--TWO 15,000 sq/ft FDA-DEA-GMP registered manufacturing labs for research, development and manufacturing from concept to commercialization
--NEW packaging line operational and adding revenue to the bottom line by making and saving the co. money
--26 employees up from 16, 2 years ago
--4 drugs in * SCALE UP *
--phentermine 15/30mg launched (April 11, 2013) is competing with Qsymia(phentermine and topiramate)
--Hong Kong Pharma NDA progressing
--MIK-001 probably an improved Embeda
--HITK's intermediate for a generic of a branded 100 million dollar drug
--first of 8 Epic drugs due out anytime(from the Stategic Epic Alliance)
--Lodrane 24 and 24D returning after being pulled by FDA with 500 other cold/flu products
--505(b)(2)opportunities's for 12 hr ART generics and NDA's where Bio-equivalency studies alone are enough (no phase III)
--Naltrexone FDA approved, launch pending (May-June 2013)
--undisclosed ANDA could come out any day
--CEO's goal is to commercialize a COMPLETE LINE of abuse resistant opiods
--Uplisting to the NASDAQ exchange per the CEO, IR indicating ASAP

HTRN: Completes Exchange Offer to Acquire Endocare

Tuesday , July 28, 2009 09:09ET

By Fain Hughes, fhughes@knobias.com

HealthTronics, Inc. (HTRN) has successfully completed the exchange offer for all of the outstanding shares of common stock of Endocare, Inc. and subsequently completed its acquisition of Endocare by a short-form merger of Endocare into a wholly-owned subsidiary of HealthTronics.

A total of 11,363,630 Endocare shares, representing approximately 91.1% of Endocare's outstanding common stock, were validly tendered and acquired in the exchange offer. Of these shares, approximately 22.9% were tendered for cash consideration and approximately 77.1% were tendered for HealthTronics common stock consideration, and therefore the stock election is oversubscribed. As a result, Endocare stockholders who elected cash consideration will receive cash and Endocare stockholders who elected stock consideration will receive, on a per Endocare share basis, approximately 0.7548 of a share of HealthTronics common stock and approximately $0.04 in cash.

YOKNEAM, Israel and PLYMOUTH MEETING, Pa., June 16, 2009 /PRNewswire via COMTEX/ --

On June 15, 2009, the Honorable William B. Chandler III, Chancellor for the State of Delaware, granted Galil Medical Ltd.'s motion for an expedited trial in Galil's recently-filed lawsuit against Endocare, Inc., arising out of Endocare's alleged breach of the Galil/Endocare Merger Agreement.

The Chancellor granted Galil's motion after oral argument, and ordered that a two-day trial would be held on July 9 and 10 in Chancery Court in Georgetown, Delaware. Chancellor Chandler further indicated that he expected to issue a judgment in the suit by July 13, 2009, the Monday following the conclusion of the scheduled trial.

Under the expedited schedule, Endocare is required to submit its answer to Galil's Complaint by June 19. Moreover, the previous termination date for the Galil/Endocare Merger Agreement (June 30) now has been extended so that Galil and Endocare will have additional time to complete their planned merger once the Chancellor rules.

Galil, a global cryotherapy company, filed the suit on June 9, 2009, to enforce the merger agreement between Galil and Endocare announced in November and to enjoin the proposed acquisition of Endocare by HealthTronics, Inc.

Martin J. Emerson, President and CEO of Galil, stated that Galil welcomed the Chancellor's decision to grant Galil's motion for an expedited trial.

He stated that, "Galil remains committed to resolving this case as quickly as possible, and then concluding our merger with Endocare. The merger between Galil and Endocare remains in the best interests of both companies, as well as the interests of the doctors and patients we serve."

About Galil Medical Galil Medical develops, manufactures and markets innovative products utilizing a proprietary cryotherapy platform that incorporates powerful freezing technology and revolutionary 17-gauge cryoablation needle design. Galil Medical's systems enable minimally invasive, targeted ablation of benign and cancerous tumors while ensuring rapid recovery and enhanced quality of life for patients. The Presice(TM) Cryoablation System features multi-point thermal sensors (MTS) and advanced IceVue(TM) planning software for excellent procedure control in treating prostate and renal cancer. The SeedNet MRI(TM) system provides physicians with an easy-to-use cryoablation solution to precisely ablate tumors while protecting adjacent structures, under MRI guidance. Galil Medical shareholders include Thomas, McNerney & Partners, The Vertical Group, Investor Growth Capital, Elron Electronic Industries Ltd. and RDC Rafael Development Corporation, Ltd. For more information, please visit . SOURCE Galil Medical Inc. Copyright (C) 2009 PR Newswire. All rights reserved

Galil: Delaware Chancery Court Grants Galil Medical Ltd.'s Motion For Expedited Proceeding In Suit Against Endocare

Last update: 6/16/2009 11:31:22 AM

HealthTronics Signs Definitive Merger Agreement With Endocare

Monday , June 08, 2009 08:00ET

AUSTIN, Texas and IRVINE, Calif., June 8, 2009 (GLOBE NEWSWIRE) -- HealthTronics, Inc. (Nasdaq:HTRN) and Endocare, Inc. (Nasdaq:ENDO) announced today that they have entered into a definitive merger agreement that has been unanimously approved by the boards of directors of each company. Prior to entering into the merger agreement with HealthTronics, Endocare terminated its merger agreement with Galil Medical Ltd. and the related private placement of its common stock on the basis that not all of the closing conditions to the merger are capable of being fulfilled.

Under the terms of the new merger agreement, HealthTronics has agreed to acquire all of the outstanding shares of Endocare common stock pursuant to an exchange offer in which Endocare stockholders can elect to receive for each Endocare share $1.35 per share in cash, provided that the cash consideration does not exceed 50% of the total consideration, or 0.7764 shares of HeathTronics' stock, provided that the stock consideration does not exceed 75% of the total consideration.

"We believe that by combining our two companies HealthTronics will solidify its position as the leading provider of products and services to the Urology community," said James Whittenburg, HealthTronics' chief executive officer. "Endocare has long been an innovator in the field of cryosurgery, and we believe our companies share a common vision of providing physicians and their patients with the best available treatment options. We are delighted to welcome the Endocare team to HealthTronics," stated Mr. Whittenburg.

"For more than a decade, Endocare has been a leading developer of cryosurgical technologies delivering effective therapeutic relief to patients with prostate cancer," stated Michael Rodriguez, Endocare's chief financial officer and co-principal executive officer. "HealthTronics has for years been an advocate and important distributor of the cryoablation technology. By joining forces, we believe that our products will have a wider adoption in the urology community, and we will have access to greater resources to market existing and emerging applications of our technology. We are very excited about the compelling strategic and financial benefits of combining our two companies."

The exchange offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Endocare common stock on a fully diluted basis, and is expected to close in the third quarter of 2009. Following completion of the exchange offer, Endocare will merge into a wholly-owned subsidiary of HealthTronics and the Endocare shares not acquired in the exchange offer will convert into the right to receive the same consideration as paid in the exchange offer. Mr. Whittenburg will be the chief executive of the combined company.

Shares of HealthTronics will continue to trade on the NASDAQ Global Select Market under the symbol "HTRN." Aspen Advisors, LP acted as financial advisor and Jackson Walker L.L.P. acted as legal counsel to HealthTronics. Oppenheimer & Co. Inc. acted as financial advisor and Gibson, Dunn & Crutcher LLP acted as legal counsel to Endocare.

Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity

Wednesday, May 27, 2009 06:00ET

IRVINE, Calif., May 27 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, today announced that on May 20, 2009 the Company received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended March 31, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

As provided in the NASDAQ Marketplace Rules, the Company has the opportunity to submit to NASDAQ a specific plan and timeline to achieve and sustain compliance. The Company intends to submit to the NASDAQ staff in a timely manner a plan to continue listing on The NASDAQ Capital Market. Under NASDAQ Marketplace Rules, the Company must submit its plan by June 4, 2009, and, if it is accepted, the Company will then be given up to 105 calendar days from the date of the May 20 letter to regain compliance.


http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6349124

HealthTronics to purchase stock for $1.25 per share

New Form 424B3, Rule 424-b3 Prospectus .... http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6343149

PROXY STATEMENT/PROSPECTUS SUPPLEMENT DATED MAY 21, 2009
(TO PROXY STATEMENT/PROSPECTUS DATED MAY 5, 2009)

This supplement (this “Supplement”) to the proxy/statement prospectus of Endocare, Inc. (“Endocare”), dated May 5, 2009, is being filed for the purpose of informing Endocare stockholders of the status of the Endocare board of directors’ review of the written proposal of HealthTronics, Inc. (“HealthTronics”) to purchase all of Endocare’s outstanding common stock for $1.25 per share, with Endocare stockholders having the ability to elect to receive either cash or HealthTronics’ common stock as consideration (the “April 2009 HealthTronics Proposal”).

At this time, in the exercise of its fiduciary duties, the Endocare board of directors continues to assess the April 2009 HealthTronics Proposal. As previously disclosed, upon concluding its evaluation of the April 2009 HealthTronics Proposal, should the Endocare board of directors determine that the April 2009 HealthTronics Proposal is not a “Superior Proposal” under the Merger Agreement with Galil Medical Ltd. (“Galil”), the Endocare board of directors will promptly provide Endocare’s stockholders with all additional information material to the stockholders regarding its evaluation, including the reasons underlying the Endocare board of directors’ conclusions regarding the Galil Merger and the April 2009 HealthTronics Proposal and the advantages of the Galil Merger over the April 2009 HealthTronics Proposal, through the filing and distribution to Endocare stockholders of an additional supplement to the proxy statement/prospectus. Endocare will provide its stockholders with at least 10 calendar days from the date the prospectus supplement containing the Endocare board of directors’ conclusions regarding the Galil Merger and the April 2009 HealthTronics Proposal is mailed prior to holding its special meeting.

Endocare stockholders should understand that, until they have received the prospectus supplement, they may not have the most up-to-date information regarding the Endocare board of directors’ evaluation of the April 2009 HealthTronics Proposal and should consider waiting to provide their proxies for the Endocare special meeting until the Endocare board of directors announces its determination with respect to the April 2009 HealthTronics Proposal. There can be no assurances that the Endocare board of directors will determine that the April 2009 HealthTronics Proposal constitutes a Superior Proposal or, if it makes such a determination, that a transaction with HealthTronics will be consummated. The Endocare board of directors has not determined that the April 2009 HealthTronics Proposal is in fact a Superior Proposal. At this time, the Endocare board of directors continues to believe that Endocare’s Merger with Galil is in the best interests of Endocare and its stockholders.

In addition, on May 14, 2009, the shareholders of Galil Medical Ltd. approved, among other things, the Merger, the Merger Agreement and the Stock Purchase Agreement.

This Supplement should be read together with the matters set forth in the proxy statement/prospectus and the annexes thereto. Capitalized terms used in this Supplement and not otherwise defined herein have the meanings ascribed to them in the proxy statement/prospectus.

Endocare stockholders and Galil shareholders may obtain additional copies of the proxy statement/prospectus and copies of this Supplement without charge by writing or calling Endocare at the following address or telephone number.

Corporate Secretary
Endocare, Inc.
201 Technology Drive
Irvine, California 92618
(949) 450-5400

This Supplement is dated May 21, 2009.

Q1 EPS (16c) vs (14c) EPS -14% Y/Y

Friday , May 15, 2009 07:43ET

QUARTER RESULTS
Endocare, Inc. (ENDO) reported Q1 results ended March 2009. Q1 Revenues were $8.18M; +0.49% vs yr-ago. Q1 EPS was (16c); -14.29% vs yr-ago.

 
  
 Q1 RESULTS      Reported      Year-Ago     Y/Y Chg      Estimate    SURPRISE 
 ----------  ------------  ------------  ----------  ------------  ---------- 
 Revenues:         $8.18M        $8.14M      +0.49%           N/A         N/A 
 ----------  ------------  ------------  ----------  ------------  ---------- 
 EPS:               (16c)         (14c)     -14.29%           N/A         N/A 
 ----------  ------------  ------------  ----------  ------------  ---------- 

So, were you aware they were hiding 10 cryo units in a warehouse for Mikus?

How's Dr. House these days?

I see he testified before congress recently.

No didnt work for USMD but did a lot of cryo cases with the Urologist that own USMD. Those guys wrote the book on cryo. I was based in New York though. I was a mobile guy.

I see. So you have a lot of inside info on the company, too. I bet you worked for USMD. Was your office in Irving?

Not true..Its actually the opposite...Most of the cryo procedures are done in the Hospital OR (I was the tech and primary trainer for 5 years). This procedure has been around for over 15 years and most physicians that use radiation use it in some form or fashion. The radiation oncologist hate it because it has proven to be more efficacious for high grade prostate cancer and tumors that Seed implants cannot treat. This procedure is approved by Medicare and many private insurance payors. It is actually being used for palliative pain therapy in cancer patients.

BraddFlipp: Is USMD still in business?

edit - nevermind - I assume this is the same company

http://www.usmdarlington.com/find_physician.php?find_specialty=28

I wish you well with your investment!

I’m personally not ready to jump on the wagon though. FWIW, I've been watching ENDO off and on since… I think maybe mid-late 2001? Heck, I can’t remember? Just the one 1-3 Split in 2007 right, no other splits prior?

Anyway, it’s a good time for mergers and acquisitions imho given the possibilities that many are going on the cheap in these times. Hopefully this will help generate market penetration and revenue moving forward? However, I think I’ll need to wait and watch for dilution, and volume, for the time being as all this comes together.

Onward Thru the Fog!!
Scov
................(hourly)

...................(weekly)

Actually, they have to get the surgery center or hospital to accept the procedure as safe.

Most of their work has been done in physician owned or controlled surgery centers.

Radiation oncologists hate this company, lol

Endocare manufactures a machine that is used to freeze prostate, kidney, lung, and liver tumors. These procedures have become more widely used now since most people want minimally invasive therapy as opposed to open surgery. The long term data on the efficacy of cryoablation is now available to physicians so they are choosing to use cryo more as a first line therapy. Cryo is also the only viable option for men with prostate cancer who have failed radiation seed therapy so usage after radiation failure will become more widespread also. Procedure volume is picking up nationwide (I still have access to the schedule lol)which should give a significant increase in Endocares income. Galil was their only major competitor so after the merger they will be the only company providing cryoablation equipment. Healthtronics (HTRN) is the mobile provider for Endocare. They provide the hospital with the equipment and the technician to do the procedure. This way the hospital just pays per case and has no capital equipment outlay. This is an excellent business model since Endocare sells everything to HTRN. All they have to do is market the procedure to physicians and they dont have to convince hospital to buy an expensive peice of equipment. The new company should go with HTRN to provide services so you may want to look at them also. All I can say is I have tripled my investment thus far. And all of this is just IMHO

How about that. I was wrong. He was at Arthur Andersen

Michael R. Rodriguez

Senior Vice President, Finance and Chief Financial Officer
From January 2004 to August 2004, Mr. Rodriguez served as a consultant to Endocare until his appointment to Senior Vice President, Finance, Chief Financial Officer and Secretary in August 2004. Prior to joining Endocare as a consultant, Mr. Rodriguez served as Executive Vice President and Chief Financial Officer of Directfit, Inc., a provider of information technology staffing services, from June 2000 to November 2003. From September 1997 to June 2000, Mr. Rodriguez held a variety of positions, including Senior Vice President and Chief Financial Officer, with Tickets.com, Inc., a publicly-traded Internet-based provider of entertainment ticketing services and software. From June 1995 to September 1997, Mr. Rodriguez was Corporate Controller and Director of Finance at EDiX Corporation, a medical informatics company. Mr. Rodriguez began his career at Arthur Andersen LLP and was with that firm from 1989 to 1993. Mr. Rodriguez holds a B.S. degree in accounting from the University of Southern California and an M.B.A. from Stanford University and he is a certified public accountant.

http://www.endocare.com/investors/management.php

Really? How about that. Was Gonzalez there when Mikus was running the show? I thought he was there. Maybe I'm not remembering right. He was interim something...

Hey Generic (lol) you got your info wrong. The old management team faced criminal charges for thier activities and were replaced. See link below

http://ocbiz.freedomblogging.com/2008/10/06/ex-ceo-of-endocare-pleads-guilty-to-200-million-fraud/3525/

This company has the same management that got them bounced to the pinks some years ago.

Tell me more.

Tell me everything!

:o)

Go for it...what cha know?

Hey Scovillez I like this one too. I worked for them for 5 years and believe me cryoablation technology is now about to take off. The merger between them and thier only competitor will allow them to corner the cryo market and expand this treatment modality. This stock was once at 9 dollars a share and can return there soon IMO. I have been loading up Lol

S-4/A, Business Combination of Endocare & Galil Medical Ltd.

PROXY STATEMENT/PROSPECTUS OF ENDOCARE, INC.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6207534

Following paragraph copy/paste from above link ... "Concurrent with the execution of the Merger Agreement, Endocare and certain existing institutional accredited stockholders of Endocare and Galil entered into a stock purchase agreement (the “Stock Purchase Agreement”), relating to the private placement by Endocare of up to 16,250,000 shares of Endocare common stock at a purchase price of $1.00 per share (the “Financing”). The offering proceeds to Endocare from the Financing are expected to be $16,250,000. The closing of the Financing is subject to the concurrent closing of the Merger and certain other conditions. Upon consummation of the Merger and the Financing and attributing ownership to Galil’s shareholders of the Escrow Shares, existing Endocare stockholders will own approximately 38.5% of Endocare’s outstanding common stock and the shareholders of Galil will own approximately 61.5% of Endocare’s outstanding common stock. As a result, the Merger will be accounted for as a reverse acquisition and equity recapitalization in accordance with U.S. generally accepted accounting principles. Under this method of accounting, after completion of the Merger and the Financing, Endocare will be treated as the “acquired” company for financial accounting and reporting purposes, and the combined entity’s results of operations prior to completion of the Merger will be those of Galil."

Endocare and Former CEO Agree to Terminate Indemnification Agreement

Wednesday, October 15, 2008 06:00ET

IRVINE, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today that it has entered into an agreement with its former CEO Paul W. Mikus that terminates Mr. Mikus' indemnification agreement in exchange for Endocare's waiver of certain severance and legal fee reimbursement rights. As a result of this new agreement, Endocare is no longer obligated to pay any future legal costs for Mr. Mikus.

Endocare CFO Michael R. Rodriguez said, "This agreement brings to a close our indemnification of former management and a long, expensive chapter for Endocare. It finally and immediately ends what has been a significant expense and allows management to focus more completely on building our business."

Endocare had previously announced a similar agreement with its former CFO. For more information regarding the agreement with Mr. Mikus, please see the related Form 8-K filed by Endocare today with the Securities and Exchange Commission.

8-K
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=5924406